glp·helper
glphelper.com/ozempic/florida/ocala
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Ocala, FL

Verified Ozempic providers in Ocala, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
32
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
33 of 33 shown

Find an Ozempic provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /ozempic/florida/{city}
§ 03Getting Ozempic in Ocala
33 providers · Ocala, FL

How to get Ozempic in Ocala.

33 GLP-1 prescribers and 7 local resource types are on record for Ocala, plus 3 nearby towns in the directory.

Prescribers in Ocala
33 prescribers
33 GLP-1 prescribers in Ocala, most listed as Internal Medicine (10), Family Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (9). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Gainesville (39 providers), Apopka (21 providers) and Clermont (30 providers).
Around the prescription in Ocala
7 listed nearby
36 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Ocala.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Ocala

Ocala, Florida has a population of 63,591 people. The adult obesity rate in Ocala is an age-adjusted estimate of 37.6%, 8 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 11.6% of adults in Ocala. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 24.9% of adults in Ocala.

of Ocala adults have obesity
37.6%
diagnosed diabetes
11.6%
no regular physical activity
24.9%

Age-adjusted estimates for Ocala, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossoral and sublingual GLP-1 options
§ 05Support around Ozempic in Ocala
6 dietitians

The prescription is one part. Here is the rest, in Ocala.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Ocala, FL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Corey Baldwin, RDN
RD
Registered dietitian
1500 Sw 1St Ave
Call 352-402-5305NPI 1518425925
Rachel Black, MS RDN
RD
Registered dietitian · Metabolic
7101 W Anthony Rd Lot 68
Call 352-514-5344NPI 1952027641
Sunny Bond, MSH, RD, LD/N
RD
Registered dietitian
3208 Se 23Rd Ave
Call 904-477-2680NPI 1558693812
Maria Botero, MS, RD, LDN, CDCES
RD
Registered dietitian
2131 Sw 20Th Pl
Call 352-368-1370NPI 1407698442
Devin Breedon, RD
RD
Registered dietitian
5100 W Highway 40 Ste 700
Call 352-462-3602NPI 1376847004
Anabelle Charles, RD
RD
Registered dietitian
6522 Sw 85Th St
Call 340-998-8151NPI 1295524163

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Kimberly Mezzetti, RDN, LDN
NUTRITIONIST
Nutritionist · Education
4826 Sw 49Th Rd
Call 561-654-6534NPI 1952908204
Sarah Zaldivar
NUTRITIONIST
Nutritionist
6501 Sw 84Th Place Rd
Call 305-492-3832NPI 1750107876
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Florida

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]